The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions

Article metrics


We investigated in ninety Caucasian pediatric patients the impact of the main polymorphisms occurring in CYP3A, CYP2D6, ABCB1 and ABCG2 genes on second-generation antipsychotics plasma concentrations, and their association with the occurrence of adverse drug reactions. Patients with the CA/AA ABCG2 genotype had a statistically significant lower risperidone plasma concentration/dose ratio (Ct/ds) (P-value: 0.007) and an higher estimated marginal probability of developing metabolism and nutrition disorders as compared to the ABCG2 c.421 non-CA/AA genotypes (P-value: 0.008). Multivariate analysis revealed that the ABCG2 c.421 CA/AA genotype was found associated to a higher hazard (P-value: 0.004) of developing adverse drug reactions classified as metabolism and nutrition disorders. The ABCB1 2677TT/3435TT genotype had a statistically significant lower aripiprazole Ct/ds if compared with patients with others ABCB1 genotypes (P-value: 0.026). Information obtained on ABCB1 and ABCG2 gene variants may result useful to tailor treatments with these drugs in Caucasian pediatric patients.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1
Figure 2


  1. 1

    Olfson M, Blanco C, Liu S-M, Wang S, Correll CU . National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012; 69: 1247–1256.

  2. 2

    Hartz I, Skurtveit S, Steffenak AKM, Karlstad O, Handal M . Psychotropic drug use among 0-17 year olds during 2004-2014: a nationwide prescription database study. BMC Psychiatry 2016; 16: 12.

  3. 3

    Bachmann CJ, Roessner V, Glaeske G, Hoffmann F . Trends in psychopharmacologic treatment of tic disorders in children and adolescents in Germany. Eur Child Adolesc Psychiatry 2015; 24: 199–207.

  4. 4

    Steinhausen H-C . Recent international trends in psychotropic medication prescriptions for children and adolescents. Eur Child Adolesc Psychiatry 2015; 24: 635–640.

  5. 5

    Verdoux H, Pambrun E, Cortaredona S, Tournier M, Verger P . Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013. Eur Child Adolesc Psychiatry 2015; 24: 1181–1191.

  6. 6

    Piovani D, Clavenna A, Cartabia M, Bonati M . Psychotropic medicine prescriptions in Italian youths: a multiregional study. Eur Child Adolesc Psychiatry 2016; 25: 235–245.

  7. 7

    Harrison JN, Cluxton-Keller F, Gross D . Antipsychotic medication prescribing trends in children and adolescents. J Pediatr Health Care 2012; 26: 139–145.

  8. 8

    Penfold RB, Stewart C, Hunkeler EM, Madden JM, Cummings J, Owen-Smith AA et al. Use of antipsychotic medications in pediatric populations: what do the data say? Curr Psychiatry Rep 2013; 15: 426.

  9. 9

    McConville BJ, Sorter MT . Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 2004; 65 : 20–29.

  10. 10

    Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT . Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14: 372–394.

  11. 11

    Pozzi M, Pisano S, Bertella S, Capuano A, Rizzo R, Antoniazzi S et al. Persistence in therapy with risperidone and aripiprazole in pediatric outpatients: a 2-year naturalistic comparison. J Clin Psychiatry 2016; 77: e1601–e1609.

  12. 12

    Correll CU . Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008; 69 : 26–36.

  13. 13

    Pisano S, Catone G, Veltri S, Lanzara V, Pozzi M, Clementi E et al. Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists. Ital J Pediatr 2016; 42: 51.

  14. 14

    Rafaniello C, Pozzi M, Pisano S, Ferrajolo C, Bertella S, Sportiello L et al. Second generation antipsychotics in ‘real-life’ paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. Expert Opin Drug Saf 2016; 15: 1–8.

  15. 15

    Ben Amor L . Antipsychotics in pediatric and adolescent patients: a review of comparative safety data. J Affect Disord 2012; 138 : S22–S30.

  16. 16

    Pringsheim T, Panagiotopoulos C, Davidson J, Ho J . Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health 2011; 16: 581–589.

  17. 17

    Pringsheim T, Panagiotopoulos C, Davidson J, Ho J . Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry 2011; 20: 218–233.

  18. 18

    Caccia S . Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatr Drugs 2013; 15: 217–233.

  19. 19

    Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl ML . Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 1999; 147: 300–305.

  20. 20

    Llerena A, Berecz R, Dorado P, de la Rubia A . QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol 2004; 18: 189–193.

  21. 21

    Leon Jde, Susce MT, Pan R-M, Wedlund PJ, Orrego ML, Diaz FJ . A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007; 40: 93–102.

  22. 22

    Kohnke MD, Griese E-U, Stosser D, Gaertner I, Barth G . Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 2002; 35: 116–118.

  23. 23

    de Leon J, Susce MT, Pan R-M, Koch WH, Wedlund PJ . Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005; 25: 448–456.

  24. 24

    de Leon J, Susce MT, Pan R-M, Fairchild M, Koch WH, Wedlund PJ . The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15–27.

  25. 25

    Bork JA, Rogers T, Wedlund PJ, de Leon J . A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999; 60: 469–476.

  26. 26

    Hiemke C, Shams M . Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry. Curr Drug Deliv 2013; 10: 46–53.

  27. 27

    de Leon J, Armstrong SC, Cozza KL . The dosing of atypical antipsychotics. Psychosomatics 2005; 46: 262–273.

  28. 28

    Spina E, de Leon J . Clinical applications of CYP genotyping in psychiatry. J Neural Transm 2015; 122: 5–28.

  29. 29

    Bradford LD . CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3: 229–243.

  30. 30

    van der Weide K, van der Weide J . The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in psychiatric patients. J Clin Psychopharmacol 2015; 35: 228–236.

  31. 31

    Xie H-G, Wood AJJ, Kim RB, Stein CM, Wilkinson GR . Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243–272.

  32. 32

    Gunes A, Spina E, Dahl M-L, Scordo MG . ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit 2008; 30: 628–633.

  33. 33

    Yoo H-D, Lee S-N, Kang H-A, Cho H-Y, Lee I-K, Lee Y-B . Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. Br J Pharmacol 2011; 164: 433–443.

  34. 34

    Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM . Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 2010; 50: 659–666.

  35. 35

    Bruhn O, Cascorbi I . Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol 2014; 10: 1337–1354.

  36. 36

    Nagasaka Y, Sano T, Oda K, Kawamura A, Usui T . Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole. Xenobiotica 2014; 44: 926–932.

  37. 37

    Ishikawa T, Tamura A, Saito H, Wakabayashi K, Nakagawa H . Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design. Naturwissenschaften 2005; 92: 451–463.

  38. 38

    Horsey AJ, Cox MH, Sarwat S, Kerr ID . The multidrug transporter ABCG2: still more questions than answers. Biochem Soc Trans 2016; 44: 824–830.

  39. 39

    Brouwer KLR, Aleksunes LM, Brandys B, Giacoia GP, Knipp G, Lukacova V et al. Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group. Clin Pharmacol Ther 2015; 98: 266–287.

  40. 40

    Konieczna A, Erdosova B, Lichnovska R, Jandl M, Cizkova K, Ehrmann J . Differential expression of ABC transporters (MDR1, MRP1, BCRP) in developing human embryos. J Mol Histol 2011; 42: 567–574.

  41. 41

    Bouwmeester NJ, Hop WCJ, van Dijk M, Anand KJS, van den Anker JN, Tibboel D . Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. Intensive Care Med 2003; 29: 2009–2015.

  42. 42

    Lam J, Baello S, Iqbal M, Kelly LE, Shannon PT, Chitayat D et al. The ontogeny of P-glycoprotein in the developing human blood-brain barrier: implication for opioid toxicity in neonates. Pediatr Res 2015; 78: 417–421.

  43. 43

    Mooij MG, Nies AT, Knibbe CAJ, Schaeffeler E, Tibboel D, Schwab M et al. Development of human membrane transporters: drug disposition and pharmacogenetics. Clin Pharmacokinet 2016; 55: 507–524.

  44. 44

    Komori M, Nishio K, Kitada M, Shiramatsu K, Muroya K, Soma M et al. Fetus-specific expression of a form of cytochrome P-450 in human livers. Biochemistry 1990; 29: 4430–4433.

  45. 45

    Stevens JC . New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. Drug Discov Today 2006; 11: 440–445.

  46. 46

    Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003; 307: 573–582.

  47. 47

    Hines RN . The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008; 118: 250–267.

  48. 48

    Pozzi M, Cattaneo D, Baldelli S, Fucile S, Capuano A, Bravaccio C et al. Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. Eur J Clin Pharmacol 2016; 72: 285–293.

  49. 49

    Schwartz GJ, Work DF . Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 2009; 4: 1832–1843.

  50. 50

    Pottel H, Mottaghy FM, Zaman Z, Martens F . On the relationship between glomerular filtration rate and serum creatinine in children. Pediatr Nephrol 2010; 25: 927–934.

  51. 51

    Gerchman F, Tong J, Utzschneider KM, Zraika S, Udayasankar J, McNeely MJ et al. Body mass index is associated with increased creatinine clearance by a mechanism independent of body fat distribution. J Clin Endocrinol Metab 2009; 94: 3781–3788.

  52. 52

    Brown EG, Wood L, Wood S . The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20: 109–117.

  53. 53

    Fine JP, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

  54. 54

    Staud F, Pavek P . Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 2005; 37: 720–725.

  55. 55

    Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665–15670.

  56. 56

    Xu J, Liu Y, Yang Y, Bates S, Zhang J-T . Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 2004; 279: 19781–19789.

  57. 57

    Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T et al. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J cancer 2002; 97: 626–630.

  58. 58

    Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215–236.

  59. 59

    Giacomini KM, Huang S-M . Transporters in drug development and clinical pharmacology. Clin Pharmacol Ther 2013; 94: 3–9.

  60. 60

    Furukawa T, Wakabayashi K, Tamura A, Nakagawa H, Morishima Y, Osawa Y et al. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm Res 2009; 26: 469–479.

  61. 61

    Wang J-S, Zhu H-J, Markowitz JS, Donovan JL, Yuan H-J, Devane CL . Antipsychotic drugs inhibit the function of breast cancer resistance protein. Basic Clin Pharmacol Toxicol 2008; 103: 336–341.

  62. 62

    Sarkadi B, Szakacs G . Understanding transport through pharmacological barriers—are we there yet? Nat Rev Drug Discov 2010; 9: 897–898.

  63. 63

    Sakurai A, Tamura A, Onishi Y, Ishikawa T . Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. Expert Opin Pharmacother 2005; 6: 2455–2473.

  64. 64

    Miller DS . Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 2010; 31: 246–254.

  65. 65

    Huang S-M, Woodcock J . Transporters in drug development: advancing on the Critical Path. Nat Rev Drug Discov 2010; 9: 175–176.

  66. 66

    Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005; 33: 165–174.

  67. 67

    Brzozowska N, Li KM, Wang XS, Booth J, Stuart J, McGregor IS et al. ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. Peer J 2016; 4: e2081.

  68. 68

    Sane R, Agarwal S, Mittapalli RK, Elmquist WF . Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system. J Pharmacol Exp Ther 2013; 345: 111–124.

  69. 69

    Lane H-Y, Liu Y-C, Huang C-L, Chang Y-C, Wu P-L, Lu C-T et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006; 26: 128–134.

  70. 70

    Lane H-Y, Chang Y-C, Cheng Y-C, Liu G-C, Lin X-R, Chang W-H . Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry 2003; 64: 316–320.

  71. 71

    Sahoo S, Mishra B, Akhtar S . Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report. Br J Clin Pharmacol 2007; 64: 715–716.

  72. 72

    Correll CU, Malhotra AK . Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology 2004; 174: 477–489.

  73. 73

    Suzuki T, Mihara K, Nakamura A, Kagawa S, Nagai G, Nemoto K et al. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 2014; 36: 651–655.

  74. 74

    Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, Usui T . Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier. Biopharm Drug Dispos 2012; 33: 304–315.

  75. 75

    Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I . Genetic analysis of the multidrug transporter. Annu Rev Genet 1995; 29: 607–649.

  76. 76

    Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR . Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277–1287.

  77. 77

    Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC . Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735–7738.

  78. 78

    Borst P, Schinkel AH, Smit JJ, Wagenaar E, Van Deemter L, Smith AJ et al. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 1993; 60: 289–299.

  79. 79

    Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I . Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265–269.

  80. 80

    Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988; 48: 1926–1929.

  81. 81

    Kirschbaum KM, Uhr M, Holthoewer D, Namendorf C, Pietrzik C, Hiemke C et al. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 2010; 59: 474–479.

  82. 82

    Wang J-S, Zhu H-J, Donovan JL, Yuan H-J, Markowitz JS, Geesey ME et al. Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr Res 2009; 110: 90–94.

  83. 83

    Virgintino D, Robertson D, Errede M, Benagiano V, Girolamo F, Maiorano E et al. Expression of P-glycoprotein in human cerebral cortex microvessels. J Histochem Cytochem 2002; 50: 1671–1676.

  84. 84

    Golden PL, Pardridge WM . P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Res 1999; 819: 143–146.

  85. 85

    Bendayan R, Ronaldson PT, Gingras D, Bendayan M . In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 2006; 54: 1159–1167.

  86. 86

    Dauchy S, Dutheil F, Weaver RJ, Chassoux F, Daumas-Duport C, Couraud P-O et al. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem 2008; 107: 1518–1528.

  87. 87

    Schuetz EG, Furuya KN, Schuetz JD . Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995; 275: 1011–1018.

  88. 88

    von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT . Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75: 172–183.

  89. 89

    Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 2007; 7: 56–65.

  90. 90

    del Moral RG, Olmo A, Aguilar M, O’Valle F . P glycoprotein: a new mechanism to control drug-induced nephrotoxicity. Exp Nephrol 1998; 6: 89–97.

  91. 91

    Pharmaceutical OA Product Information: ABILIFY MAINTENA intramuscular injection extended-release suspension, aripiprazole intramuscular injection extended-release suspension 2014.

  92. 92

    Eli Lilly and Company. Product Information: PROZAC(R) oral capsules, delayed-release capsules, solution, fluoxetine oral capsules 2008.

  93. 93

    Sportiello L, Rafaniello C, Sullo MG, Nica M, Scavone C, Bernardi FF et al. No substantial gender differences in suspected adverse reactions to ACE inhibitors and ARBs: results from spontaneous reporting system in Campania Region. Expert Opin Drug Saf 2016; 15: 101–107.

  94. 94

    Mascolo A, Rafaniello C, Sportiello L, Sessa M, Cimmaruta D, Rossi F et al. Dipeptidyl peptidase (DPP)-4 inhibitor-induced arthritis/arthralgia: a review of clinical cases. Drug Saf 2016; 39: 401–407.

  95. 95

    Sessa M, Rossi C, Rafaniello C, Mascolo A, Cimmaruta D, Scavone C et al. Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions. Expert Opin Drug Saf 2016; 15: 51–59.

  96. 96

    Sportiello L, Rafaniello C, Scavone C, Vitale C, Rossi F, Capuano A . The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy. Int J Cardiol 2016; 202: 731–735.

Download references

Author information

Correspondence to C Rafaniello.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website

Supplementary information

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rafaniello, C., Sessa, M., Bernardi, F. et al. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J 18, 422–430 (2018) doi:10.1038/tpj.2017.38

Download citation

Further reading